Page 1

NEKTAR THERAPEUTICS New Rezpegaldesleukin Data Supporting Long - term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 October 1 , 2026 Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications , reinforcing the differentiated properties of this novel Treg mechanism In alopecia areata patients , SALT Score ≤20 response maintained in 75 % at 4 months off treatment and in 63 % at six months off treatment Hair regrowth continued for 6 months off treatment with 19 % of patients achieving SALT Score ≤10 , an improvement from 7 % at the end of 52 weeks of treatment Third Phase 3 study in the global ZENITH AD program initiated , expanding the program into treatment- experiencedatopicdermatitispatients ; Phase3ZENITHAAstudytoinitiate in early 2027 Companytohostconferencecallwithinvestorsandanalystsat8 : 00 AMET/2 : 00 PM CET SAN FRANCISCO and VIENNA , Oct. 1 , 2026 / PRNewswire / -- Nektar Therapeutics ( Nasdaq : NKTR ) today announced that long - term data on rezpegaldesleukin from the Phase 2b REZOLVE - AA and Phase 2b REZOLVE - AD studies are being presented at the European Academy of Dermatology and Venereology ( EADV ) Congress 2026 in Vienna , Austria in two oral presentation sessions . NEKTAR Bold immune science . Transformative immune health . At EADV 2026 , data from the 52 - week treatment extension cohort and the 6 - month off - treatment period in the global Phase 2b REZOLVE - AA study in patients with severe - to - very - severe alopecia areata are being presented by Dr. David Rosmarin , Chair of Dermatology , Indiana University School of Medicine in an oral presentation entitled " Rezpegaldesleukin , a Novel Regulatory TCell - Inducing Biologic , Demonstrates Efficacy and Safety in Severe - to - Very - Severe Alopecia Areata : 52 - Week Results from the Phase 2b REZOLVE - AA Study " [ link to presentation ] . " These data demonstrate that one year of treatment with rezpegaldesleukin can result in lasting and even deepening hair regrowth with these same effects continuing for six months off - treatment in the majority of patients , " said David Rosmarin , M.D. , Chair of the Department of Dermatology and Associate Professor of Dermatology at Indiana University School of Medicine . " As a novel Treg - targeted mechanism , rezpegaldesleukin is designed to address the underlying immune dysregulation in patients with alopecia areata . To date , we have not seen this degree of both sustained benefit and further hair regrowth after treatment cessation with existing systemic therapies for alopecia areata . These findings suggest that rezpegaldesleukin may offer a fundamentally different approach to managing this chronic disorder and could emerge as a preferred first - line treatment option in the future for patients seeking durable disease control . " Highlights from 52 - Week Results in REZOLVE - AA Phase 2b Study in Alopecia Areata ( Including Off - Treatment Durability ) : • A total of 31 patients continued into a blinded 16 - week treatment extension after 36 weeks of initial treatment with 27 patients in the twice - monthly rezpegaldesleukin dose arms ( low dose of 18 µg / kg , n = 14 ) and ( high dose of 24 µg / kg , n = 13 ) . • As previously reported , continued rezpegaldesleukin treatment through Week 52 demonstrated clear and consistent separation from placebo on key measures of efficacy . From Week 36 to Week 52 , 29 % of patients at low dose and 31 % of patients at high dose achieved new SALT Score ≤20 responses as compared to none in the placebo arm . A SALT Score ≤20 is achieved when a patient has 80 % or more of their scalp covered by hair . • SimilarEfficacy Demonstrated in Patients Irrespective of Duration of Current Episode : A new subgroup analysis of all patients who entered the 52 - week treatment extension showed similar efficacy data regardless of current alopecia areata